tirzepatide and cardiovascular outcomes Cardiovascular Outcomes with Tirzepatide Compared with Dulaglutide in Patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice

23.48

★★★★☆4.8 (126)

In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%

22.52

★★★★★4.9 (98)

Cardiovascular effects of tirzepatide

24.72

★★★★★5.0 (157)

❇️ Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes 🟠BACKGROUND Tirzepatide, a dual incretin agonist of the glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, has favorable effects on

29.17

★★★★★4.7 (84)

SUMMIT trial results presented at #AHA24 show tirzepatide reduced the risk of worsening heart failure events and improved quality of life in patients with #HFpEF and obesity. “Cardiologists now have an ever-expanding

29.62

★★★★★4.9 (203)

💉 In a large real-world study, tirzepatide was associated with a lower incidence of major cardiovascular outcomes vs semaglutide: 📊 Composite CV outcome: 1.90% vs 2.18% (HR 0.86, p=0.01) ❤️ New-onset heart

28.23

★★★★★5.0 (176)

Effects of tirzepatide, a dual GIP and GLP-1 receptor agonist, on blood pressure, cardiac function, and sympathetic nervous system in stroke-prone spontaneously hypertensive rats

27.83

★★★★★4.8 (132)